Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells

Neuroendocrinology Letters

Volumn 33, Issue SUPPL. 3, 2012, Pages 16-24

  Groh, Tomas ^a,b   Hrabeta, Jan ^b   Poljakova, Jitka ^a   Eckschlager, Tomas ^b   Stiborova, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Cell cycle; Cytotoxicity; Etoposide; Neuroblastoma; Valproic acid

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ETOPOSIDE; LIPOCORTIN 5; PROPIDIUM IODIDE; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL HYPOXIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; SENSITIZATION;

EID: 84874802943     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Agner J, Falck J, Lukas J and Bartek J (2005) Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Exp Cell Res 302: 162-169. (Pubitemid 39550459)
2. Baldwin EL and Osheroff N (2005) Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 5: 363-372. (Pubitemid 40974810)
3. Belani CP, Doyle LA and Aisner J (1994) Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer Chemother Pharmacol 34 Suppl: S118-126. (Pubitemid 24264056)
4. Blaheta RA and Cinatl J, Jr. (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22: 492-511.
5. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
6. Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O et al. (2005) Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90: 1383-1389. (Pubitemid 40463993)
7. Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, et al. (2007) Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 35: 1032-1041. (Pubitemid 46956421)
8. Cinatl J, Jr., Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B et al. (1997) Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 8: 958-963. (Pubitemid 28027094)
9. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70: 369-413.
10. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM and Liu LF (1984) Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259: 13560-13566. (Pubitemid 15221834)
11. Das CM, Zage PE, Taylor P, Aguilera D, Wolff JE, Lee D et al. (2010) Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur J Cancer 46: 2771-2780.
12. Eyal S, Lamb JG, Smith-Yockman M, Yagen B, Fibach E and Altschuler Y (2006) White HS, Bialer M. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol 149: 250-260. (Pubitemid 44453425)
13. Daud Al, Dawson J, Deconti RC, Bicaku E, Marchion D, Bastien S et al. (2009) Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 15: 2479-2487.
14. Hajji N, Wallenborg K, Vlachos P, Fullgrabe J, Hermanson O and Joseph B (2010) Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide. Oncogene 29: 2192-2204.
15. Hrebackova J, Hrabeta J and Eckschlager T (2010) Valproic acid in the complex therapy of malignant tumors. Curr Drug Targets 11: 361-379.
16. Imbert TF (1998) Discovery of podophyllotoxins. Biochimie 80: 207-222.
17. Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM et al. (2006) The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 91: 248-251.
18. Kawashiro T, Yamashita K, Zhao XJ, Koyama E, Tani M, Chiba K, et al. (1998) A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 286: 1294-1300. (Pubitemid 29135542)
19. Krishan A, Paika K and Frei E, 3rd (1975) Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts. J Cell Biol 66:521-530.
20. Lee JH, Choy ML, Ngo L, Foster SS and Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A 107: 14639-14644.
21. Li J, Hua HM, Tang YB, Zhang S, Ohkoshi E, Lee KH et al. (2012) Synthesis and evaluation of novel podophyllotoxin analogs. Bioorg Med Chem Lett 22: 4293-4295.
22. Loike JD and Horwitz SB (1976) Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 15: 5443-5448. (Pubitemid 8004252)
23. Marchion DC, Bicaku E, Daud Al, Sullivan DM and Munster PN (2005) In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 4: 1993-2000. (Pubitemid 43056982)
24. Marchion DC, Bicaku E, Daud Al, Richon V, Sullivan DM and Munster PN (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92: 223-237.
25. Meresse P, Dechaux E, Monneret C and Bertounesque E (2004) Etoposide: discovery and medicinal chemistry. Curr Med Chem 11: 2443-2466. (Pubitemid 39172359)
26. Nelson EM, Tewey KM and Liu LF (1984) Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A 81: 1361-1365 (Pubitemid 14173469)
27. Obata S, Yamaguchi Y and Miyamoto T (1990) Effects of etoposide (VP-16) on the survival and progression of cultured HeLa S3 cells through the cell cycle. Nihon Gan Chiryo Gakkai Shi 25: 2484-2491. (Pubitemid 20376417)
28. Olive PL and Banath JP (1993) Detection of DNA double-strand breaks through the cell cycle after exposure to X-rays, bleomycin, etoposide and 125IdUrd. Int J Radiat Biol 64: 349-358. (Pubitemid 23313338)
29. Perez C, Pelayo F, Vilaboa NE and Aller P (1994) Caffeine attenuates the action of amsacrine and etoposide in U-937 cells by mechanisms which involve inhibition of RNA synthesis. Int J Cancer 57: 889-893. (Pubitemid 24216827)
30. Poljakova J, Hrebackova J, Dvorakova M, Moserova M, Eckschlager T, Hrabeta J et al. (2011) Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. Neuro Endocrinol Lett 32 (Suppl 1): 101-116.
31. Robert J and Larsen AK (1998) Drug resistance to topoisomerase II inhibitors. Biochimie 80: 247-254. (Pubitemid 28206040)
32. Santini V, Gozzini A and Ferrari G (2007) Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 8: 383-393.
33. Schonn I, Hennesen J and Dartsch DC (2010) Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage. Apoptosis 15: 162-172.
34. Schroeder U, Bernt KM, Lange B, Wenkel J, Jikai J, Shabat D et al. (2003) Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia. Blood 102: 246-253. (Pubitemid 36759661)
35. Stacey DW, Hitomi M and Chen G (2000) Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity. Mol Cell Biol 20: 9127-9137. (Pubitemid 32246102)
36. Stiborova M, Eckschlager T, Poljakova J, Hrabeta J, Adam V, Kizek R et al. (2012) The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Curr Med Chem 19: 4218-4238.
37. Stiborova M, Moserova M, Mrazova B, Kotrbova V and Frei E (2010) Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney. Neuro Endocrinol Lett 31 (Suppl. 2): 26-35.
38. Stiborova M, Rupertova M, and Frei E (2011) Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim Biophys Acta 1814: 175-185.
39. Tanaka T, Halicka HD, Traganos F, Seiter K and Darzynkiewicz Z (2007) Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase. Cell Cycle 6: 371-376.
40. Tewey KM, Rowe TC, Yang L, Halligan BD and Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466-468. (Pubitemid 14012819)
41. Uesaka T, Shono T, Kuga D, Suzuki SO, Niiro H, Miyamoto K et al. (2007) Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. J Neurooncol 84: 119-129. (Pubitemid 47202120)
42. Van Der Graaf WT and De Vries EG (1990) Mitoxantrone: blue-beard for malignancies. Anticancer Drugs 1: 109-125.
43. Vrzal R Doricakova A, Novotna A, Bachleda P, Bitman M, Pavek P, et al. (2011) Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia? Toxicol Lett 200:146-153.
44. Walker JV and Nitiss JL (2002) DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 20: 570-589. (Pubitemid 34686351)
45. Wozniak AJ and Ross WE (1983) DNA damage as a basis for 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res 43: 120-124. (Pubitemid 13172805)
46. Zhao XJ, Kawashiro T and Ishizaki T (1998) Mutual inhibition between quinine and etoposide by human liver microsomes. Evidence for cytochrome P4503A4 involvement in their major metabolic pathways. Drug Metab Dispos 26: 188-191. (Pubitemid 28104089)
47. Zheng N, Pang S, Oe T, Felix CA, Wehrli S and Blair IA (2006) Characterization of an etoposide-glutathione conjugate derived from metabolic activation by human cytochrome p450. Curr Drug Metab 7: 897-911. (Pubitemid 44873714)